MG96077 is a novel, broad spectrum, non-beta-lactam beta-lactamase inhibitor designed to overcome beta-lactamase mediated antibiotic resistance. MG96077 exhibits a broad-spectrum inhibitory profile for both class A and class C beta-lactamase enzymes. In addition, the compound overcomes resistance in beta-lactam-resistant organisms such as Pseudomonas aeruginosa and Klebsiella pneumoniae.

MG96077 is in advanced preclinical development and ready to commence IND-enabling studies.

Worldwide rights to MG96077 are available for licensing.

Business Development Contacts

Jessica M. Corson, MBA

Director, Business Development
Mirati Therapeutics, Inc.
Tel: 858.332.3410 –

Disclaimer | Privacy Policy | © Mirati Therapeutics, 2013.
Website design: Solo Communications

Subscribe to News

Please fill out the form below to be added to Mirati's press release distribution list.

Your Name (required)

Your Company

Your Email (required)